Technical Analysis for DARE - Dare Bioscience, Inc.

Grade Last Price % Change Price Change
D 1.87 -3.11% -0.06
DARE closed down 3.11 percent on Friday, February 26, 2021, on 23 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical DARE trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
50 DMA Support Bullish -3.11%
Lower Bollinger Band Walk Weakness -3.11%
Below Lower BB Weakness -3.11%
Lower Bollinger Band Touch Weakness -3.11%
Older End-of-Day Signals for DARE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Support about 21 hours ago
Down 5% about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago
Rose Above Lower Bollinger Band about 22 hours ago
50 DMA Resistance about 22 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Dare Bioscience, Inc. Description

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Drugs Vagina Diaphragm Reproductive Health Women's Health Hormonal Contraception Medroxyprogesterone Acetate

Is DARE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.85
52 Week Low 0.75
Average Volume 3,382,835
200-Day Moving Average 1.30
50-Day Moving Average 1.90
20-Day Moving Average 2.23
10-Day Moving Average 2.12
Average True Range 0.22
ADX 23.04
+DI 19.08
-DI 31.20
Chandelier Exit (Long, 3 ATRs ) 1.91
Chandelier Exit (Short, 3 ATRs ) 2.40
Upper Bollinger Band 2.57
Lower Bollinger Band 1.89
Percent B (%b) -0.03
BandWidth 30.42
MACD Line -0.01
MACD Signal Line 0.07
MACD Histogram -0.0812
Fundamentals Value
Market Cap 71.04 Million
Num Shares 38 Million
EPS -1.05
Price-to-Earnings (P/E) Ratio -1.77
Price-to-Sales 0.00
Price-to-Book 131.82
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.08
Resistance 3 (R3) 2.08 2.02 2.05
Resistance 2 (R2) 2.02 1.96 2.02 2.03
Resistance 1 (R1) 1.94 1.93 1.94 1.94 2.02
Pivot Point 1.88 1.88 1.88 1.88 1.88
Support 1 (S1) 1.80 1.82 1.80 1.80 1.72
Support 2 (S2) 1.74 1.79 1.74 1.71
Support 3 (S3) 1.66 1.74 1.70
Support 4 (S4) 1.66